Abstract
Targeting cancer chemotherapy with SMANCS/Lipiodol for hepatocellular carcinoma has been used for more than 20 years. We believe it is important to reconfirm the characteristics of SMANCS/Lipiodol, and refine the method of administration and management of adverse effects in order to achieve satisfactory outcome. In this report, we reveal some clinical cases not only HCC but also other malignant solid tumors through our experience of 20 years. We experienced great many patients who received the arterially targeted cancer chemotherapy with SMANCS/Lipiodol for 20 years, so we would like to introduce various cases of different kinds of cancers and organic features when we perform arterial administration of SMANCS/Lipiodol.
